D. B. Duignan

发表

Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

S. C. Panchal, Philip B. Cox, P. Hajduk, 2020, Journal of medicinal chemistry.

Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective

David B Duignan, Jonathan A Phillips, Jinping Gan, 2017, Experimental biology and medicine.

Prediction of Biliary Excretion in Rats and Humans Using Molecular Weight and Quantitative Structure–Pharmacokinetic Relationships

Marilyn E. Morris, D. B. Duignan, M. Morris, 2009, The AAPS Journal.

Fit-for-purpose LC-MS/MS quantification of leukotoxin and leukotoxin diol in mouse plasma without sample pre-concentration.

Christian Goess, D. B. Duignan, Gary J. Jenkins, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The development and validation of a computational model to predict rat liver microsomal clearance.

E. Gifford, D. B. Duignan, Kjell Johnson, 2009, Journal of pharmaceutical sciences.

Understanding the clinical pharmacokinetics of a GABAA partial agonist by application of in vitro tools

D. B. Duignan, F. Nelson, R. Obach, 2010, Xenobiotica; the fate of foreign compounds in biological systems.

Optimized protein kinase Cθ (PKCθ) inhibitors reveal only modest anti-inflammatory efficacy in a rodent model of arthritis.

D. B. Duignan, P. Honore, S. Mittelstadt, 2015, Journal of medicinal chemistry.

ffi cacy in a Rodent Model of Arthritis

D. B. Duignan, P. Honore, S. Mittelstadt, 2014 .

Synthesis, SAR and pharmacology of CP-293,019: a potent, selective dopamine D4 receptor antagonist.

D. B. Duignan, A. Fliri, P. Seymour, 1998, Bioorganic & medicinal chemistry letters.

Discovery of selective and orally bioavailable protein kinase Cθ (PKCθ) inhibitors from a fragment hit.

D. B. Duignan, P. Honore, S. Mittelstadt, 2015, Journal of medicinal chemistry.

Sphingosine-1-Phosphate (S1P) Lyase Inhibition Causes Increased Cardiac S1P Levels and Bradycardia in Rats

D. B. Duignan, G. Gintant, J. Segreti, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

Assessment of a Micropatterned Hepatocyte Coculture System to Generate Major Human Excretory and Circulating Drug Metabolites

D. B. Duignan, R. Obach, S. Khetani, 2010, Drug Metabolism and Disposition.

A 96-well efflux assay to identify ABCG2 substrates using a stably transfected MDCK II cell line.

D. B. Duignan, Yongling Xiao, S. D. de Morais, 2006, Molecular pharmaceutics.

Microphysiological systems for ADME-related applications: current status and recommendations for system development and characterization.

Stephen Fowler, Wen Li Kelly Chen, David B Duignan, 2020, Lab on a chip.

Expression and characterization of canine cytochrome P450 2D15.

D. B. Duignan, D. Tweedie, R. Obach, 1998, Archives of biochemistry and biophysics.

Prodrugs for colon-restricted delivery: Design, synthesis, and in vivo evaluation of colony stimulating factor 1 receptor (CSF1R) inhibitors

Lu Wang, David B Duignan, D. B. Duignan, 2018, PloS one.

Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.

Bo Feng, David B Duignan, D. B. Duignan, 2009, Toxicological sciences : an official journal of the Society of Toxicology.

Use of Cryopreserved Human Hepatocytes in Sandwich Culture to Measure Hepatobiliary Transport

Diana Kazolias, D. B. Duignan, Y. Bi, 2006, Drug Metabolism and Disposition.

Purification and characterization of the dog hepatic cytochrome P-450 isozyme responsible for the metabolism of 2,2',4,4',5,5'-hexachlorobiphenyl.

D. B. Duignan, J. Halpert, I. Sipes, 1986, Archives of biochemistry and biophysics.

Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human

Bo Feng, David B Duignan, Sabrina X Zhao, 2007, Drug Metabolism and Disposition.

Characterization of Digoxin Uptake in Sandwich-Cultured Human Hepatocytes

D. B. Duignan, Yongling Xiao, Jonathan Chupka, 2011, Drug Metabolism and Disposition.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

D. B. Duignan, B. Feng, T. Goosen, 2011, Molecular pharmaceutics.

Quantitative expression profile of hepatobiliary transporters in sandwich cultured rat and human hepatocytes.

Na Li, David B Duignan, Yurong Lai, 2009, Molecular pharmaceutics.

The metabolism of xenobiotics and endogenous compounds by the constitutive dog liver cytochrome P450 PBD-2.

D. B. Duignan, J. Halpert, I. Sipes, 1988, Archives of biochemistry and biophysics.

Selective inactivation by chloramphenicol of the major phenobarbital-inducible isozyme of dog liver cytochrome P-450.

D. B. Duignan, J. Halpert, P. Ciaccio, 1987, Drug metabolism and disposition: the biological fate of chemicals.

High throughput ADME screening: practical considerations, impact on the portfolio and enabler of in silico ADME models.

David B Duignan, John S Janiszewski, Theodore E Liston, 2008, Current drug metabolism.